Magali Gilles

Marseille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Modulating Chikungunya and Mayaro virus-induced disease severity in mice using low concentrations of anti-IFNAR1 antibodies.

Modulating Chikungunya and Mayaro virus-induced disease severity in mice using low concentrations of anti-IFNAR1 antibodies.

Journal: Emerging microbes & infections

Published: January 14, 2026

Virological characterization of SARS-CoV-2 BA.2.86 variants by assessing antiviral susceptibility, in vivo infectivity and replicative fitness.

Virological characterization of SARS-CoV-2 BA.2.86 variants by assessing antiviral susceptibility, in vivo infectivity and replicative fitness.

Journal: Scientific reports

Published: June 24, 2025

Current status of pathogen handling in European laboratories: focus on viral inactivation process.

Current status of pathogen handling in European laboratories: focus on viral inactivation process.

Journal: Frontiers in bioengineering and biotechnology

Published: April 24, 2024

Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages.

Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: December 05, 2023

Long-Term Infectivity of Chikungunya Virus Stored in the Dark at 4°C.

Long-Term Infectivity of Chikungunya Virus Stored in the Dark at 4°C.

Journal: Vector borne and zoonotic diseases (Larchmont, N.Y.)

Published: December 27, 2021

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2.

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2.

Journal: EBioMedicine

Published: December 17, 2021

Replicative Fitness of a SARS-CoV-2 20I/501Y.V1 Variant from Lineage B.1.1.7 in Human Reconstituted Bronchial Epithelium.

Replicative Fitness of a SARS-CoV-2 20I/501Y.V1 Variant from Lineage B.1.1.7 in Human Reconstituted Bronchial Epithelium.

Journal: mBio

Published: July 06, 2021

Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2).

Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2).

Journal: PloS one

Published: July 02, 2021

Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.

Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.

Journal: Antiviral research

Published: November 17, 2020

Prolonged Infectivity of SARS-CoV-2 in Fomites.

Prolonged Infectivity of SARS-CoV-2 in Fomites.

Journal: Emerging infectious diseases

Published: June 25, 2020

Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics?

Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics?

Journal: Viruses

Published: May 18, 2020

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.

Journal: Scientific reports

Published: May 12, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026